Synergistic Chemoimmunotherapy of Hepatocellular Carcinoma via ROS-Responsive Carrier-Free Prodrug Nanoparticles
Nano Letters · 2026
DOI: 10.1021/acs.nanolett.5c05725 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nano Letters, 2026. Verfasst von Bin Zhou und 14 weiteren Autor:innen. Beteiligte Einrichtung: The Second Affiliated Hospital and Yuying Children's Hospital, Wenzhou Medical University, Wenzhou, Zhejiang 325000, China. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Reactive Oxygen Species, Prodrugs. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 50 Literaturangaben. Gefördert von: Discipline Cluster of Oncology, Wenzhou Medical University, Wenzhou Key Laboratory of Research and Transformation of Chinese Medicine, Fundamental Research Program of Shanxi Province.
Abstract (Originalsprache)
Carrier-free nanomedicines, with their high drug-loading capacity and low carrier-associated toxicity, offer a promising strategy for synergistic cancer therapy. Here, we developed a reactive oxygen species (ROS)-responsive, carrier-free nanoparticle (PRO/OCA NP) self-assembled from a resveratrol prodrug (PRO) and the immune adjuvant obeticholic acid (OCA). The oxalate ester linkage enabled selective cleavage in the ROS-enriched tumor microenvironment, ensuring precise co-release of Res and OCA. This dual delivery suppressed hepatocellular carcinoma (HCC) proliferation, induced apoptosis and cell cycle arrest, and inhibited PI3K/AKT/mTOR signaling. Meanwhile, PRO/OCA NPs trigger immunogenic cell death in tumor cells, activating NK and NKT cells and enhancing their cytotoxic functions, thereby amplifying the innate immune responses. In an orthotopic HCC mouse model, PRO/OCA markedly inhibited both primary and metastatic tumors while exhibiting favorable biocompatibility. Compared with monotherapy or simple drug combinations, this platform achieves a "1 + 1 > 2" chemo-immunotherapeutic synergy, offering a strategy with translational potential for comprehensive HCC treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The Second Affiliated Hospital and Yuying Children's Hospital, Wenzhou Medical University, Wenzhou, Zhejiang 325000, China.
- State Key Laboratory of Macromolecular Drugs and Large-scale Preparation, School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang 325035, China.
- Faculty of Pharmaceutical Sciences, Burapha University, Chonburi, 20131, Thailand.
- Stem Cell Translation Laboratory, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Third Hospital of Shanxi Medical University, Taiyuan, Shanxi 030032, China.
- Zhejiang Key Laboratory of Ophthalmic Drug Discovery and Medical Device Research, Eye Hospital, Wenzhou Medical University, Wenzhou 325027, China.
- Zhejiang Engineering Research Center for Tissue Repair Materials, Wenzhou Institute, University of Chinese Academy of Sciences, Wenzhou 325001, China.
ORCID-Profile: Zhiguo Liu, Jianliang Shen
Förderung
- Discipline Cluster of Oncology, Wenzhou Medical University
- Wenzhou Key Laboratory of Research and Transformation of Chinese Medicine
- Fundamental Research Program of Shanxi Province
- Summit Advancement Disciplines of Zhejiang Province (Wenzhou Medical University - Pharmaceutics)
Zitieren
APA
Zhou, B., Zhong, X., Cheng, C., Wang, Z., Bai, B., Zhu, F., Wang, Z., Shi, W., Wang, Y., Liu, Z., Werayachankul, T., Hu, J., Shen, J., Yang, L., & Zhao, C. (2026). Synergistic Chemoimmunotherapy of Hepatocellular Carcinoma via ROS-Responsive Carrier-Free Prodrug Nanoparticles. Nano Letters. https://doi.org/10.1021/acs.nanolett.5c05725
Vancouver
Zhou B, Zhong X, Cheng C, Wang Z, Bai B, Zhu F, et al. Synergistic Chemoimmunotherapy of Hepatocellular Carcinoma via ROS-Responsive Carrier-Free Prodrug Nanoparticles. Nano Letters. 2026. doi:10.1021/acs.nanolett.5c05725
BibTeX
@article{Zhou2026,
author = {Zhou, Bin and Zhong, Xihao and Cheng, Chen and Wang, Zhaohong and Bai, Binglong and Zhu, Fanyun and Wang, Zijian and Shi, Wenjian and Wang, Yuedong and Liu, Zhiguo and Werayachankul, Thiyapha and Hu, Jie and Shen, Jianliang and Yang, Lehe and Zhao, Chengguang},
title = {Synergistic Chemoimmunotherapy of Hepatocellular Carcinoma via ROS-Responsive Carrier-Free Prodrug Nanoparticles},
journal = {Nano Letters},
year = {2026},
doi = {10.1021/acs.nanolett.5c05725}
}
EUVIMED